605 Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models

• Marcin Kowanetz,
• Po Ho,
• Shelley Ackerman,
• Heidi LeBlanc,
• David Dornan,
• Michael Alonso,
• Cecelia Pearson,
• Andrew Luo,
• Richard Laura,
• Justin Kenkel,
• LIsa Blum,
• Angela Luo,
• Matthew Zhou,
• Joshua Gregorio,
• Brian Safina

Affiliations

Marcin Kowanetz

Aff1 grid.418158.10000000405344718Genentech, Inc. San Francisco CA USA

Po Ho

Aff56 Corvus Pharmaceuticals Burlingame CA USA

Shelley Ackerman

19Bolt Biotherapeutics, Redwood City, CA, USA

Heidi LeBlanc

19Bolt Biotherapeutics, Redwood City, CA, USA

David Dornan

19Bolt Biotherapeutics, Redwood City, CA, USA

Michael Alonso

19Bolt Biotherapeutics, Redwood City, CA, USA

Cecelia Pearson

1Bolt Biotherapeutics, Redwood City, CA, USA

Andrew Luo

1Bolt Biotherapeutics, Redwood City, CA, USA

Richard Laura

1Bolt Biotherapeutics, Redwood City, CA, USA

Justin Kenkel

Bolt Biotherapeutics

LIsa Blum

Bolt Biotherapeutics

Angela Luo

Bolt Biotherapeutics

Matthew Zhou

Bolt Biotherapeutics

Joshua Gregorio

Bolt Biotherapeutics

Brian Safina

Bolt Biotherapeutics